Join the BioNap Email List!

Wednesday, January 11, 2017

JPM Meeting Notes - Actinium Pharmaceuticals (ATNM)


During my meeting with Actinium Pharmaceuticals (ATNM) we delved deeper into the topic I covered via a separate article last week – the clinical hold placed on Seattle Genetics SGN-CD33A. I can go into a lot more detail if necessary, but I think if investors read that article above they will get the picture. I do not believe there is a meaningful risk of hepatotoxicity or VDO with Iomab-B or Actimab-A. The problem is that ADCs, for all their promise, just do not seem to be well tolerated.

In the meantime, Actinium has a catalyst-rich year ahead, headlined by at least one DMC analysis on Phase 3 SIERRA (potentially two) and further looks at the ongoing Actimab-A Phase 2 results. Management told me to be on the look-out for a new potential indication for Actimab-A later in the year, but would not spill the beans even though I tried pretty hard to pry it out of them. I’m not expecting that until the second quarter.

The most near-term update from the company may come at the BMT Tandem meeting taking place in February 2017 (#BMT17 ← you heard it hear first). This is the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) – it’s a rowdy bunch. Nevertheless, it’s starting to gain more and more attention from Wall Street. I do not know if we will see any new data from the company at BMT Tandem, but it does make sense for Actinium to establish a presence at the event. After all, it’s the target market for the company’s products.

----------

Please see important information about BioNap and our relationship with companies mentioned above our Disclaimer.
BioNap holds no position in shares of ATNM.

6 comments:

  1. Thanks. Any partner discussion? Did they have a presence at JPM?

    ReplyDelete
    Replies
    1. I got the sense they are definitely talking to people, but I would not expect anything during the first half of 2017. I think they are focused on getting both trials moving forward. Partners are watching.

      Delete
  2. Jason,
    Thanks for all of your insights.
    Question - you said ADC's have a bad track record. What is your feeling about Gilead's ADC which in Ph1-2b got 9/9 complete responses with no major side effects? Do you view that as a threat to Actimab-A and do you think it being included in the "Beat AML" trial is a negative for Actinium?

    ReplyDelete
    Replies
    1. Not sure what GILD ADC you are talking about.
      GILD is working on entospletinib, a tyrosine kinase inhibitor in combo with 7+3 for AML patients that can tolerate 7+3. That's not an ADC.
      And it's not even the same target market for Actimab-A.

      What GILD ADC are you referring to?

      Delete
  3. Just reread your ATNM update here. With current activity, I'm getting pretty excited for 2017 and Actinium

    ReplyDelete
  4. Were you attending the BMT Tandem meetings at all? Seems to be a huge gathering with a lot of big players there.

    ReplyDelete